Gilgamesh Pharmaceuticals

+39%

est. 2Y upside i

HealthcareSeries B

Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…

Rank

#1224

Sector

Biotechnology / Pharmaceuticals

Est. Liquidity

~3Y

Data Quality

Data: Medium

Gilgamesh offers moderate upside (~39%) over 2 years, but with significant clinical and regulatory risk.

Last updated: July 19, 2026

Bull (25%)+105%

Positive Phase 3 results or IPO window expand multiple to 18x on $125M revenue, exit $2.25B. After 20% dilution, 105% upside.

Base (55%)+36%

Multiple converges to 12.5x on $125M revenue, exit $1.56B. After 20% dilution, 36.25% upside.

Bear (20%)-34%

Multiple compresses to 8x, exit $1B. After $136M preference, common recovers $864M, then 20% dilution yields -33.6% downside.

Est. time to liquidity~2.5 years

Preference Stack Risk

moderate

Funding Intensity

14%

Total funding $136M is 13.6% of $1B valuation, falling in the moderate overhang range.

Dilution Risk

high

Given limited runway from 2022 Series B and high cash burn, a capital raise within 2 years is likely, diluting existing shareholders by ~20%.

Secondary Liquidity

none

No secondary market activity detected; employee shares are illiquid until a liquidity event.

Other — 1 role

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Gilgamesh Pharmaceuticals's data — designed to show you've done your homework.

1
“How do you prioritize pipeline candidates given limited resources?”
2
“What is your view on the competitive landscape with other psychedelic companies?”
3
“How do you assess the potential of a secondary market for employee equity?”

Our model estimates +39% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.